Previous 10 | Next 10 |
--News Direct-- BioVie CEO Cuong Do joins Proactive's Natalie Stoberman to share the details of the company's upcoming BioVie Day webinar on March 23. Do says BioVie Day will feature a comprehensive overview of the company’s programs in Alzheimer’s disease, Parkinson’...
CARSON CITY, Nev., March 14, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...
2023-03-13 13:59:32 ET Clinical-stage biotech BioVie ( NASDAQ: BIVI ) announced Monday that the company halted patient enrollment in Phase 2b clinical trial for ascites candidate BIV201 after generating "compelling" data from its first 15 patients. The study is designed to e...
CARSON CITY, Nev., March 13, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...
2023-03-10 11:04:28 ET Shares of clinical-stage biotech company BioVie (NASDAQ: BIVI) were up 19.2% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence . The stock closed last week at $6.87 and rose to a high of $9.40 on Thursd...
CARSON CITY, Nev., March 09, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...
2023-03-06 09:17:30 ET BioVie ( NASDAQ: BIVI ) announces additional preliminary findings from its Parkinson’s Disease (PD) Phase 2 trial. The findings show that significantly more patients treated with the Company’s drug, NE3107, were assessed as being in...
CARSON CITY, Nev., March 06, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...
Shares of clinical-stage biotech BioVie (NASDAQ: BIVI) rose 51.7% in February, according to data provided by S&P Global Market Intelligence . The healthcare company closed out January at $5.07, then rose to $7.88 on Feb. 28. It's worth noting that the run continued after the m...
CARSON CITY, Nev., March 02, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver di...
News, Short Squeeze, Breakout and More Instantly...
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Ti...
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopa/levodopa Additional presentation at congress highlighted data from earlier Phase 2a trial of bezisterim in Parkinson...
ORLANDO, FL / ACCESSWIRE / June 21, 2024 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Mobilicom Ltd. (Nasdaq:MOB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 22, at 7 p.m. Eastern Time (ET). Bloomb...